Tags

Type your tag names separated by a space and hit enter

Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis.
Int J Cancer 2009; 124(3):698-712IJ

Abstract

Epidemiological evidence indicates that the association between body weight and breast cancer risk may differ across menopausal status as well as the estrogen receptor (ER) and progesterone receptor (PR) tumor status. To date, no meta-analysis has been conducted to assess the association between body weight and ER/PR defined breast cancer risk, taking into account menopausal status and study design. We searched MEDLINE for relevant studies published from January 1, 1970 through December 31, 2007. Summarized risk estimates with 95% confidence intervals (CIs) were calculated using a random-effects model. The summarized results of 9 cohorts and 22 case-control studies comparing the highest versus the reference categories of relative body weight showed that the risk for ER+PR+ tumors was 20% lower (95% CI=-30% to -8%) among premenopausal (2,643 cases) and 82% higher (95% CI=55-114%) among postmenopausal (5,469 cases) women. The dose-response meta-analysis of ER+PR+ tumors showed that each 5-unit increase in body mass index (BMI, kg/m2) was associated with a 33% increased risk among postmenopausal women (95% CI=20-48%) and 10% decreased risk among premenopausal women (95% CI=-18% to -1%). No associations were observed for ER-PR- or ER+PR- tumors. For discordant tumors ER+PR- (pre) and ER-PR+ (pre/post) the number of cases were too small (<200) to interpret results. The relation between body weight and breast cancer risk is critically dependent on the tumor's ER/PR status and the woman's menopausal status. Body weight control is the effective strategy for preventing ER+PR+ tumors after menopause.

Authors+Show Affiliations

Institute of Environmental Medicine, Division of Nutritional Epidemiology, Karolinska Institutet, Stockholm, Sweden.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Meta-Analysis
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

18988226

Citation

Suzuki, Reiko, et al. "Body Weight and Incidence of Breast Cancer Defined By Estrogen and Progesterone Receptor Status--a Meta-analysis." International Journal of Cancer, vol. 124, no. 3, 2009, pp. 698-712.
Suzuki R, Orsini N, Saji S, et al. Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis. Int J Cancer. 2009;124(3):698-712.
Suzuki, R., Orsini, N., Saji, S., Key, T. J., & Wolk, A. (2009). Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis. International Journal of Cancer, 124(3), pp. 698-712. doi:10.1002/ijc.23943.
Suzuki R, et al. Body Weight and Incidence of Breast Cancer Defined By Estrogen and Progesterone Receptor Status--a Meta-analysis. Int J Cancer. 2009 Feb 1;124(3):698-712. PubMed PMID: 18988226.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Body weight and incidence of breast cancer defined by estrogen and progesterone receptor status--a meta-analysis. AU - Suzuki,Reiko, AU - Orsini,Nicola, AU - Saji,Shigehira, AU - Key,Timothy J, AU - Wolk,Alicja, PY - 2008/11/7/pubmed PY - 2008/12/31/medline PY - 2008/11/7/entrez SP - 698 EP - 712 JF - International journal of cancer JO - Int. J. Cancer VL - 124 IS - 3 N2 - Epidemiological evidence indicates that the association between body weight and breast cancer risk may differ across menopausal status as well as the estrogen receptor (ER) and progesterone receptor (PR) tumor status. To date, no meta-analysis has been conducted to assess the association between body weight and ER/PR defined breast cancer risk, taking into account menopausal status and study design. We searched MEDLINE for relevant studies published from January 1, 1970 through December 31, 2007. Summarized risk estimates with 95% confidence intervals (CIs) were calculated using a random-effects model. The summarized results of 9 cohorts and 22 case-control studies comparing the highest versus the reference categories of relative body weight showed that the risk for ER+PR+ tumors was 20% lower (95% CI=-30% to -8%) among premenopausal (2,643 cases) and 82% higher (95% CI=55-114%) among postmenopausal (5,469 cases) women. The dose-response meta-analysis of ER+PR+ tumors showed that each 5-unit increase in body mass index (BMI, kg/m2) was associated with a 33% increased risk among postmenopausal women (95% CI=20-48%) and 10% decreased risk among premenopausal women (95% CI=-18% to -1%). No associations were observed for ER-PR- or ER+PR- tumors. For discordant tumors ER+PR- (pre) and ER-PR+ (pre/post) the number of cases were too small (<200) to interpret results. The relation between body weight and breast cancer risk is critically dependent on the tumor's ER/PR status and the woman's menopausal status. Body weight control is the effective strategy for preventing ER+PR+ tumors after menopause. SN - 1097-0215 UR - https://www.unboundmedicine.com/medline/citation/18988226/Body_weight_and_incidence_of_breast_cancer_defined_by_estrogen_and_progesterone_receptor_status__a_meta_analysis_ L2 - https://doi.org/10.1002/ijc.23943 DB - PRIME DP - Unbound Medicine ER -